Literature DB >> 29579414

Triggers of inflammatory myopathy: insights into pathogenesis.

Brittany L Adler1, Lisa Christopher-Stine1.   

Abstract

The inflammatory myopathies, which include dermatomyositis, polymyositis, and the immune-mediated necrotizing myopathies, are a heterogeneous group of autoimmune diseases that manifest with muscle, skin, or lung damage. Collectively, these autoimmune diseases result from loss of tolerance to a select group of self-antigens, although the precise mechanism through which this occurs is not known. Infection, malignancy, and certain medications including statins and the immune checkpoint inhibitors used in cancer therapy have been identified as potential immunologic triggers of the inflammatory myopathies. Some of these triggers are classically associated with specific myositis-specific autoantibodies (MSAs). The strong association between certain triggers and MSAs provides insights into how an immunologic event can lead to loss of tolerance to specific self-antigens, resulting in autoimmune disease. In this review, we discuss the proposed triggers of the inflammatory myopathies and their associations with MSAs, and provide insights into how these triggers may result in the inflammatory myopathies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29579414      PMCID: PMC5921929     

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  65 in total

1.  HTLV-1 and polymyositis in Jamaica.

Authors:  O S Morgan; P Rodgers-Johnson; C Mora; G Char
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

Review 2.  Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.

Authors:  Michael A Postow; Robert Sidlow; Matthew D Hellmann
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

Review 3.  Management of immune-related adverse events and kinetics of response with ipilimumab.

Authors:  Jeffrey S Weber; Katharina C Kähler; Axel Hauschild
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

4.  Dermatomyositis associated with the presence of parvovirus B19 DNA in muscle.

Authors:  G Chevrel; A Calvet; V Belin; P Miossec
Journal:  Rheumatology (Oxford)       Date:  2000-09       Impact factor: 7.580

Review 5.  Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.

Authors:  Laura C Cappelli; Anna Kristina Gutierrez; Clifton O Bingham; Ami A Shah
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-09-21       Impact factor: 4.794

6.  Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects.

Authors:  Andrew L Mammen; Katherine Pak; Emma K Williams; Diane Brisson; Joe Coresh; Elizabeth Selvin; Daniel Gaudet
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

7.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

Authors:  Richard A Morgan; Nachimuthu Chinnasamy; Daniel Abate-Daga; Alena Gros; Paul F Robbins; Zhili Zheng; Mark E Dudley; Steven A Feldman; James C Yang; Richard M Sherry; Giao Q Phan; Marybeth S Hughes; Udai S Kammula; Akemi D Miller; Crystal J Hessman; Ashley A Stewart; Nicholas P Restifo; Martha M Quezado; Meghna Alimchandani; Avi Z Rosenberg; Avindra Nath; Tongguang Wang; Bibiana Bielekova; Simone C Wuest; Nirmala Akula; Francis J McMahon; Susanne Wilde; Barbara Mosetter; Dolores J Schendel; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

8.  Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset.

Authors:  C Manlhiot; L Liang; D Tran; A Bitnun; P N Tyrrell; B M Feldman
Journal:  Rheumatology (Oxford)       Date:  2008-02-27       Impact factor: 7.580

9.  Myositis associated with interleukin-2 therapy in a patient with metastatic renal cell carcinoma.

Authors:  F J Esteva-Lorenzo; J E Janik; R G Fenton; A Emslie-Smith; A G Engel; D L Longo
Journal:  Cancer       Date:  1995-10-01       Impact factor: 6.860

10.  Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy.

Authors:  Masato Kadoya; Ayumi Hida; Meiko Hashimoto Maeda; Kenichiro Taira; Chiseko Ikenaga; Naohiro Uchio; Akatsuki Kubota; Kenichi Kaida; Yusuke Miwa; Kazuhiro Kurasawa; Hiroyuki Shimada; Masahiro Sonoo; Atsuro Chiba; Yasushi Shiio; Yoshikazu Uesaka; Yasuhisa Sakurai; Toru Izumi; Manami Inoue; Shin Kwak; Shoji Tsuji; Jun Shimizu
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-10-07
View more
  14 in total

1.  Dermatomyositis: immunological landscape, biomarkers, and potential candidate drugs.

Authors:  Ruxue Yin; Gangjian Wang; Lei Zhang; Tianfang Li; Shengyun Liu
Journal:  Clin Rheumatol       Date:  2021-01-03       Impact factor: 2.980

2.  A case of anti-HMGCR myopathy triggered by sodium/glucose co-transporter 2 (SGLT2) inhibitors.

Authors:  Manuela Stella; Erica Biassoni; Chiara Fiorillo; Marina Grandis; Francesca Mattioli; Massimo Del Sette
Journal:  Neurol Sci       Date:  2022-04-07       Impact factor: 3.307

3.  Disruption of the endopeptidase ADAM10-Notch signaling axis leads to skin dysbiosis and innate lymphoid cell-mediated hair follicle destruction.

Authors:  Keiko Sakamoto; Seon-Pil Jin; Shubham Goel; Jay-Hyun Jo; Benjamin Voisin; Doyoung Kim; Vinod Nadella; Hai Liang; Tetsuro Kobayashi; Xin Huang; Clay Deming; Keisuke Horiuchi; Julia A Segre; Heidi H Kong; Keisuke Nagao
Journal:  Immunity       Date:  2021-09-27       Impact factor: 43.474

4.  Delayed-onset Necrotizing Myositis following COVID-19 Infection.

Authors:  Sravani Lokineni; Mahta Mortezavi
Journal:  Eur J Case Rep Intern Med       Date:  2021-04-20

Review 5.  Mechanisms underlying direct actions of hyperlipidemia on myocardium: an updated review.

Authors:  Yu Si Yao; Tu Di Li; Zhi Huan Zeng
Journal:  Lipids Health Dis       Date:  2020-02-08       Impact factor: 3.876

6.  Anti-HMGCR myopathy misdiagnosed as motor neuron disease and complicated with COVID-19 infection.

Authors:  Andrea Barp; Daniele Velardo; Patrizia Ciscato; Valeria Ada Sansone; Christian Lunetta
Journal:  Neurol Sci       Date:  2021-03-01       Impact factor: 3.307

7.  Gemcitabine and Docetaxel Combination Chemotherapy Induced Dermatomyositis Associated with Hand-Foot Syndrome.

Authors:  Mayuko Kawada; Kazunari Sugita; Ayako Ito; Osamu Yamamoto
Journal:  Indian J Dermatol       Date:  2021 Jan-Feb       Impact factor: 1.494

8.  Life-Threatening Myositis in a Patient With EGFR-Mutated NSCLC on Osimertinib: Case Report.

Authors:  Fionnuala Crowley; Bailey G Fitzgerald; Aarti S Bhardwaj; Irine Siraj; Cardinale Smith
Journal:  JTO Clin Res Rep       Date:  2021-12-04

9.  Necrotizing myositis in a rectus muscle arising in the setting of long-standing Langerhans cell histiocystosis and recent dabrafenib treatment.

Authors:  Suzanne W van Landingham; Diane Puccetti; Heather Potter; David Gamm; Eli L Diamond; Mark J Lucarelli
Journal:  Am J Ophthalmol Case Rep       Date:  2020-08-13

Review 10.  New Onset of Autoimmune Diseases Following COVID-19 Diagnosis.

Authors:  Abraham Edgar Gracia-Ramos; Eduardo Martin-Nares; Gabriela Hernández-Molina
Journal:  Cells       Date:  2021-12-20       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.